InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: Corundum post# 26421

Monday, 03/22/2021 12:46:01 PM

Monday, March 22, 2021 12:46:01 PM

Post# of 43139

Some issues with Kiniksa's Mavrilimumab study


Thanks! I bought some KNSA on the assumption that the stock is priced a little low even without the Covid angle. A press release announcing a new government-funded Covid study would be gravy. Big Pharma could even buy mavrilimumab. The GM-CSF trial news is still new information that is undoubtedly being discussed behind the scenes. I'll hold on to KNSA for awhile to see if anything materializes. With the KNSA's stock price not rising on last Thursday's FDA approval for pericarditis, my guess is that news will at least prevent the stock price from falling much.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.